TD Cowen analyst Marc Frahm downgraded Repare Therapeutics (RPTX) to Hold from Buy after the company agreed to be acquired by XenoTherapeutics for an estimated $1.82 per share. TD sees little risk to the deal closing.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX: